Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgeryAetna Facial Nerve Paralysis Coverage Update | Ope…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0745

    Facial Nerve Paralysis

    Customize your policy alerts

    Sign up for Aetna Policy 0745 alerts

    Get alerted when Policy 0745 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This Aetna clinical policy bulletin governs diagnostic testing and surgical and non‑surgical treatments for facial nerve paralysis (including Bell's palsy) and specifies which procedures and therapies are considered medically necessary or experimental/investigational for Aetna members.

    Policy Summary
    PayerAetna
    PolicyFacial Nerve Paralysis
    Policy CodePolicy 0745
    Change TypeNo material change
    Effective DateFeb 8, 2008
    Last ReviewFeb 20, 2024
    Next Review DateAug 8, 2024
    Key ActionObtain prior authorization and document duration of paralysis, severity (House-Brackmann), and objective electrophysiologic testing (ENoG/EMG) when requesting facial reconstructive or decompression surgery.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3Medically necessary items
    20+Experimental/investigational items
    G51.0ICD-10
    18 trialsCochrane dataset
    94.4% vs 81.6%Prednisolone recovery benefit

    Coverage Criteria and Evidence Summaries

    inv-01: Medically necessary diagnostic and therapeutic interventions

    Covered when the following specific conditions are met:

    Diagnostic tests considered medically necessary: Blink reflex testing for diagnosis of Bell's palsy is medically necessary.

    Supported by policy statement listing blink reflex testing as medically necessary.

    Eyelid implant: Gold weight eyelid implants are medically necessary for treatment of Bell's palsy-related lagophthalmos.

    Supported by policy statement listing gold weight eyelid implants as medically necessary.

    Facial reconstructive surgery (anastomosis/grafts/muscle transfer)

    • Eligibility criteria: (1) Facial paralysis has persisted for more than 12 months; and (2) Facial paralysis has resulted in impaired functional deficit in mastication, speech, or vision; and (3) There is no reasonable likelihood of spontaneous return of function as determined by electromyography or electroneuronography.
    Policy Summary
    PayerAetna
    PolicyFacial Nerve Paralysis
    Policy CodePolicy 0745
    Change TypeNo material change
    Effective DateFeb 8, 2008
    Last ReviewFeb 20, 2024
    Next Review DateAug 8, 2024
    Key ActionObtain prior authorization and document duration of paralysis, severity (House-Brackmann), and objective electrophysiologic testing (ENoG/EMG) when requesting facial reconstructive or decompression surgery.
    SourceLink
    On This Page
    Coverage Criteria and Evidence SummariesPrior Authorization, Documentation, and Step TherapyCodes and BillingDefinitions and Background
    duration: > 12 months

    These three elements must all be present.

    inv-02: Experimental and investigational (Not covered)

    The following are considered experimental and investigational for the diagnosis or treatment of Bell's palsy:

    Diagnostic tests considered investigational: Genetic analysis of facial muscle specimens; measurement of blood total/native thiol and disulphide activity as a pathogenetic marker; neuromuscular ultrasound.

    Effectiveness not established.

    Therapies considered investigational: Acupuncture; anti-viral therapy; botulinum toxin; electrical stimulation; facial nerve decompression; facial retraining therapy; hyperbaric oxygen therapy; infrared therapy; intra-tympanic steroid injection; Kinesio taping; laser acupuncture; nerve growth factor; neural therapy; peripheral blood mononuclear cells and platelet-rich plasma transplantation; photobiomodulation; proprioceptive neuromuscular facilitation; transcranial magnetic stimulation; vitamin B-12 therapy.

    Listed as experimental/investigational due to lack of established effectiveness.

    inv-03: Medical (steroids ± antivirals) – evidence summary

    Summary of evidence-based coverage considerations

    Medical therapy for new-onset Bell's palsy: Offer systemic corticosteroids initiated early (within ~72 hours to 7 days of symptom onset) to increase the probability of complete recovery; antivirals alone do not improve recovery, and antivirals added to steroids provide at most modest and inconsistent additional benefit.timing: within 72 hours to 7 days

    Based on Sullivan et al (randomized factorial trial) and meta-analyses showing corticosteroid benefit and limited antiviral benefit.

    inv-04: Physical therapy (exercises, electrostimulation, acupuncture)

    Physical therapy / rehabilitation

    Physical therapies: Tailored facial exercises (mirror, EMG biofeedback, neuromuscular re-training) have low- to moderate-quality evidence of benefit for chronic or moderate paralysis and may reduce sequelae in some acute cases; electrostimulation and acupuncture lack high-quality evidence of consistent benefit.varies by study

    Based on systematic reviews (Teixeira et al) and small trials; evidence heterogeneous and generally low quality.

    inv-05: Surgery and reanimation – evidence and timing

    Surgical management and reanimation

    Surgical decompression: Randomized trial evidence for surgical decompression in Bell's palsy is very limited and of very low quality; reported risks include sensorineural hearing loss and vertigo. Consider decompression only in well-selected patients with objective evidence and after counseling about risks.consider only in well-selected patients

    Cochrane review found very low-quality evidence from small trials.

    Reconstructive procedures for long-standing paralysis: Reconstructive options include early nerve repair/grafting when timely, cross-facial nerve grafting with staged free functional muscle transfer, single-stage masseteric nerve–driven free muscle transfer, and temporalis or masseter transpositions; selection depends on duration (>12 months), etiology, patient factors, and goals.typically after ~12 months without recovery for consideration of reanimation surgery

    Based on surgical series and expert reviews describing staged approaches and indications.

    inv-06: Surgical reanimation: evidence summaries

    Surgical reanimation approaches and indications summarized from case series and reviews:

    Surgical reanimation general: Immediate nerve repair/grafting is favored when onset is recent and target muscles remain viable; for irreversible unilateral complete palsy a staged approach (cross-facial nerve grafting followed by free functional muscle transfer) is commonly used; in patients with limited life expectancy, masseteric or temporalis transfers may be preferred.

    Recommendations based on expert reviews and large case series.

    Alternative single-stage option: Single-stage free gracilis transfer innervated by the masseteric nerve can produce voluntary smile recovery within months and has been reported with satisfactory outcomes in small series.

    Supported by small case series (Momeni, Chuang).

    Bilateral palsy: Bilateral free gracilis transfers using masseteric nerve branches are reported options for bilateral facial palsy.

    Reported in surgical series and reviews.

    inv-07: Adjunctive and conservative therapy: evidence summaries

    Adjunct and conservative treatments with summarized findings:

    Corticosteroids for Bell's palsy: Systemic corticosteroids are effective and represent standard initial therapy; adding antivirals does not consistently improve outcomes except possibly in some severe cases.

    Cochrane and randomized trial evidence support corticosteroid benefit (Sullivan et al, Gagyor et al).

    Intra-tympanic steroids: Combined systemic and intra-tympanic corticosteroids may reduce non-recovery in some studies, particularly with daily ITST regimens, but methods vary and further RCTs are needed.

    Meta-analysis of RCTs and cohorts (Fujiwara et al) suggests potential benefit with daily ITST.

    Acupuncture +/- vitamin B12: Acupuncture trials are heterogeneous and at high risk of bias; acupuncture combined with vitamin B12 showed lower incomplete recovery rates in some small studies but evidence quality is limited.

    Systematic reviews/meta-analyses report inconsistent findings and methodological limitations.

    Botulinum toxin for synkinesis: Botulinum toxin injections can improve facial symmetry and quality of life for synkinesis in chronic facial palsy, though evidence is limited and further RCTs are needed.

    Systematic reviews and small studies report benefit for BTX in chronic synkinesis.

    Electrical stimulation: Evidence does not show clear added benefit of electrical stimulation over multimodal physiotherapy; routine use is not recommended without controlled trial evidence.

    Systematic reviews and small trials report mixed or no benefit.

    Nerve growth factor (NGF): Meta-analysis of small RCTs showed favorable effects on response rate for NGF, but trials are few and low quality, so evidence is insufficient for routine use.

    Limited RCT data (Su et al meta-analysis).

    inv-08: Diagnostics and biomarkers

    Diagnostic modalities evaluated:

    Neuromuscular ultrasound: Ultrasound can detect facial nerve enlargement with reported sensitivity ~75% and specificity ~70%; current technique lacks sensitivity for routine diagnosis but may be useful for assessment or follow-up.sensitivity ~75%

    Pilot study (Tawfik et al) reported these performance characteristics.

    Thiol/disulphide biomarker: Preliminary study found lower total and native thiol and higher disulphide levels in Bell's palsy with a reported disulphide cut-off of 18.95; these findings require validation.disulphide > 18.95

    Prospective study (Babademez et al) — preliminary research.

    inv-09: Facial nerve decompression — selection criteria

    Surgical facial nerve decompression (selected statements from literature): Covered when ALL of the following are met

    Decompression candidate criteria: 1) Complete facial paralysis or severe dysfunction (eg, House-Brackmann grade V–VI); and 2) Electrophysiologic testing consistent with severe degeneration (eg, >90% on electroneuronography and absent voluntary EMG within ~14 days); and 3) Timing appropriate for the chosen approach — middle cranial fossa decompression (MFD) ideally within 14 days for best outcomes (some series suggest benefit if performed within 90 days when earlier surgery is not possible); and 4) Patient counseled on risks (including reported risk of sensorineural hearing loss) and that return of maximal function may be delayed up to 12 months.ENoG > 90% degeneration; timing: MFD ≤14 days (optimal)

    Derived from Andresen, Casazza, Berania observational series and reviews.

    inv-10: Post-paralytic synkinesis — staged care

    Management of post-paralytic synkinesis: consider the following sequence

    Synkinesis management sequencing: 1) First-line: chemodenervation with botulinum toxin and neuromuscular re‑training; and 2) If refractory: consider selective myectomy, selective neurectomy, or reanimation procedures (eg, free muscle transfer) individualized to the patient; and 3) Surgical options should be considered after multidisciplinary discussion and when benefits outweigh limited evidence and potential need for revision surgery.N/A

    Based on systematic review and clinical practice recommendations that describe surgery as third-line.

    inv-11: Complementary and experimental interventions — informational

    Complementary, experimental, or low-quality evidence interventions noted in literature

    Nonstandard interventions with limited evidence: Nerve growth factor (NGF), thiol/disulphide biomarker measurement, neural therapy, acupuncture (including laser/acupoint techniques), Kinesio taping, photobiomodulation, peripheral blood mononuclear cell + PRP transplantation, proprioceptive neuromuscular facilitation, and other novel modalities have preliminary or low-quality evidence only and require further well-designed trials.N/A

    Informational summary of heterogeneous, generally low-quality literature.

    inv-12: Consideration for selective neurectomy

    Selective neurectomy may be considered only when ALL of the following are met:

    Required conditions: 1) Patient has post‑paralytic synkinesis producing functional impairment or reduced quality of life; and 2) Adequate documented trials of first‑line therapies (botulinum toxin chemodenervation and neuromuscular re‑training) have been attempted without sufficient benefit; and 3) Patient has been counseled about limited evidence, potential complications, and variable success rates; and 4) Multidisciplinary consideration of alternative surgical options has occurred.

    Based on systematic review findings and international recommendations that surgery is third‑line and should be individualized.

    Specific procedures, devices, and supplies that are listed as experimental and investigational in this bulletin are excluded from coverage for the indications addressed. Examples include (but are not limited to) acupuncture; anti‑viral therapy; botulinum toxin; electrical stimulation; facial nerve decompression; facial retraining therapy; hyperbaric oxygen therapy; infrared therapy; intra‑tympanic steroid injection; Kinesio taping; laser acupuncture; nerve growth factor; neural therapy; peripheral blood mononuclear cells and platelet‑rich plasma transplantation; photobiomodulation; neuromuscular ultrasound; genetic analysis; and measurement of blood thiol/disulphide activity. Relevant not‑covered HCPCS/CPT supply and device codes are listed in the coding section and correspond to items on the investigational list.

    Osteopathic and chiropractic manipulation have been used in some case reports and small series, but the available literature does not provide sufficient scientific evidence to support their effectiveness for Bell’s palsy. Accordingly, these manual therapies are considered experimental and investigational for this indication and are not supported as covered treatments.

    Routine use of electrical nerve stimulation for Bell’s palsy is not recommended. Small trials and reviews do not demonstrate clear added benefit over multimodal physiotherapy or spontaneous recovery, and controlled trial evidence and comprehensive safety data are lacking; therefore electrical stimulation is listed as experimental and investigational for this indication and related stimulator supplies are included among non‑covered HCPCS codes.

    There is very low‑certainty evidence from randomized trials regarding early surgical intervention for Bell’s palsy; existing systematic reviews and RCTs are insufficient to determine benefit or harm. Because spontaneous recovery or medically supported recovery occurs in most cases, the evidence does not support routine early surgery and surgical approaches remain investigational except in carefully selected circumstances with appropriate objective testing and counseling.

    Selective neurectomy and other synkinesis‑directed surgeries are not recommended as first‑line therapy. These procedures should not be performed without prior discussion of risks and recognition that long‑term outcomes data are limited; current practice recommendations describe selective myectomy/neurectomy as a third‑line option after less invasive therapies have been attempted.

    Any procedure or therapy appearing on the experimental/investigational list (for example, acupuncture, botulinum toxin, electrical stimulation, hyperbaric oxygen, PRP injections, neuromuscular ultrasound, genetic testing, photobiomodulation, etc.) is considered not established for the indications in this bulletin and therefore is not medically necessary for treatment of Bell’s palsy unless later evidence demonstrates effectiveness.

    High‑quality evidence from pooled trials indicates that anti‑herpes simplex antivirals when used alone do not provide a significant benefit over placebo for complete recovery in Bell’s palsy. As a result, antivirals without concurrent corticosteroid therapy are considered not medically necessary as sole therapy for this condition.

    Systematic reviews and meta‑analyses of acupuncture and related therapies show heterogeneous methods, high risk of bias, and incomplete safety reporting. While some pooled analyses report higher ‘effective response’ rates, the overall evidence is insufficient to conclusively support routine use; therefore acupuncture and similar complementary therapies are considered experimental and investigational for Bell’s palsy.

    Routine surgical decompression for early management of Bell’s palsy is not supported by high‑certainty randomized trial evidence. Meta‑analyses and reviews report very limited and low‑certainty data; thus decompression is not established as standard care except in carefully selected patients who meet objective electrodiagnostic and timing criteria and who have been counseled about potential risks.

    Selective neurectomy performed without documented prior conservative management (including documented trials of botulinum toxin chemodenervation and neuromuscular retraining), and without individualized counseling regarding limited evidence and possible complications, is considered not medically necessary for treatment of post‑paralytic synkinesis.

    Prior Authorization, Documentation, and Step Therapy

    Prior Authorization

    Prior Authorization Required for Surgical/Interventional Codes

    Prior authorization is required for surgical and interventional CPT/HCPCS codes related to facial reconstructive and reanimation procedures. Requests should include supporting clinical documentation demonstrating that selection criteria are met before services are scheduled.

    • Prior authorization required for complex facial reconstructive/reanimation CPT/HCPCS codes
    • Authorization must document that selection criteria (e.g., duration >12 months, functional deficit, lack of spontaneous recovery on EMG/ENoG) are met
    Prior Authorization

    Prior Authorization for Facial Reanimation

    Prior authorization should be obtained for elective facial reanimation surgeries. Given limited high-quality randomized evidence, authorization is appropriate only when documentation supports medical necessity and conservative measures have been attempted or are not reasonable.

    • Authorization expected for cross-facial nerve grafting, free functional muscle transfer, hypoglossal or masseteric nerve transfers, temporalis transposition, and related microvascular procedures
    • Include rationale for surgery (cause of lesion, duration, prior treatments, functional deficits)
    Prior Authorization

    Authorization When Surgical Decompression Is Proposed

    When facial nerve decompression is proposed, prior authorization must include objective evidence of severe paralysis and electrophysiologic testing supporting irrecoverable nerve degeneration. Documentation should justify surgical timing and approach.

    • Required: House-Brackmann grade, duration since onset, and ENoG showing >90% degeneration or absent voluntary EMG when applicable
    • Document proposed surgical approach (middle cranial fossa vs transmastoid), timing from symptom onset (e.g., ≤14 days vs >14 days), and expected benefits/risks
    Prior Authorization

    Prior Authorization Expectation for Selective Neurectomy

    Selective neurectomy (SN) is considered a third-line, adjunctive surgical option for post-paralytic synkinesis and requires prior authorization only after failure or inadequate response to first-line therapies. Provide documentation of prior non-surgical management and rationale for SN.

    • Authorization expected only after documented trials of botulinum toxin (chemo-denervation) and neuromuscular re‑training
    • Document targeted symptoms (synkinesis type), prior Botox dosing/frequency and response, duration of non-surgical therapy, and planned extent of neurectomy/myectomy
    Denial Risk

    Experimental/Investigational Exclusions Trigger Denial

    Procedures and therapies designated as experimental or investigational will be denied. Prior authorization requests for these services should not be approved unless new, high-quality evidence justifies coverage.

    • Services considered experimental/investigational: genetic analysis of facial muscle specimens, neural therapy, neuromuscular ultrasound (for diagnosis), blood thiol/disulphide testing, injection of platelet-rich plasma for this indication, photobiomodulation, acupuncture modalities listed
    • Facial nerve decompression is listed among investigational treatments for Bell's palsy in portions of the policy — evaluate per indication and evidence; some decompression indications (selected trauma/time-limited) may be considered with documented criteria
    Note

    Surgical Intervention Evidence Limited — Authorization Requires Careful Justification

    Surgical interventions for Bell's palsy and other causes of facial paralysis have limited high-quality randomized evidence. Authorization decisions should reflect the uncertain benefit and the need for individualized clinical justification.

    • Randomized evidence is very limited (small trials, low quality) and observational data guide much of current practice
    • Authorization requires clear documentation of failure of conservative/medical therapy and objective measures supporting the anticipated benefit
    Note

    Outcome Expectations for Alternative Motor Nerve Procedures

    When alternative motor-nerve–based procedures (e.g., temporalis transposition, hypoglossal or accessory nerve neurotization) are proposed, prior authorization should set outcome expectations: these approaches may restore movement but often do not produce a spontaneous smile and outcomes differ from facial-nerve–based reinnervation.

    • Document patient counseling about expected functional outcomes (e.g., temporalis transfers may produce voluntary but not spontaneous smile)
    • Indicate reasons for selecting motor-nerve–based procedure (e.g., comorbidities, limited life expectancy, prior failed procedures)
    Documentation Required

    Objective Electrophysiologic Confirmation Recommended Prior to Decompression

    Objective electrophysiologic confirmation is recommended before authorizing facial nerve decompression. ENoG and EMG findings, when documented, should support the absence of spontaneous recovery potential.

    • Include electroneuronography (ENoG) percent degeneration and EMG showing absent voluntary motor unit potentials where applicable
    • Specify timing of tests relative to symptom onset and correlate with proposed surgical timing
    Note

    Evidence Limitations May Affect Authorization

    Evidence limitations (heterogeneity, small studies, observational designs) may affect authorization outcomes. Decisions should be individualized, and surgery generally considered third-line after noninvasive options have been exhausted.

    • Authorization may be denied or limited when documentation does not address evidence gaps or fails to demonstrate prior appropriate therapies
    • Consider multidisciplinary evaluation and second-opinion documentation when evidence is limited
    Documentation Required

    Required Documentation for Facial Reconstructive Surgery

    For facial reconstructive surgery (anastomosis, fascia slings, muscle transposition, cross-facial nerve grafting with microvascular muscle transfer), provide comprehensive operative planning and prior-treatment documentation to support medical necessity.

    • Document duration of paralysis (>12 months for chronic procedures) and absence of meaningful spontaneous recovery
    • Functional impairment described (mastication, speech, vision), prior EMG/ENoG results demonstrating lack of recovery potential, and rationale for chosen reconstructive technique
    • Include prior non-operative therapies and outcomes, patient counseling regarding expected results and staged procedures
    Documentation Required

    Required Clinical Documentation Elements

    Authorization requests must include key clinical documentation elements to establish medical necessity and appropriate sequencing of care.

    • Timing of treatment initiation (e.g., within 72 hours or 7 days for medical therapy where applicable) and time since onset of paralysis
    • Diagnostic exclusion of alternate causes (e.g., zoster sine herpete) when relevant, and test results (ENoG, EMG, imaging)
    • Functional status measures (House-Brackmann grade, Yanagihara or eFACE scores), and documentation of impact on activities (mastication, speech, vision)
    Documentation Required

    Required Clinical Documentation for Surgical Reanimation

    For surgical reanimation requests, include detailed clinical history and objective findings demonstrating appropriateness of the procedure and timing.

    • Onset timing and etiology of lesion; prior treatments and responses (medical, Botox, re-training)
    • Objective functional status (House-Brackmann grade), electrophysiologic testing results, and imaging when performed
    • Rationale for selected reanimation technique (cross-facial grafting vs masseteric or hypoglossal transfers), staged treatment plan, and expected functional outcomes
    Documentation Required

    Required Clinical Documentation for Decompression Consideration

    For consideration of decompression surgery, include documentation of the degree and timing of paralysis plus electrophysiologic testing that supports the need for decompression versus continued medical management.

    • House-Brackmann grade at presentation, timing since onset, and indication for decompression approach (MFD vs TMD)
    • ENoG percent degeneration (e.g., >90%) or absent voluntary EMG within recommended windows, and imaging when performed
    • If decompression is delayed, document reason and expected benefit given literature suggesting timing influences outcomes
    Documentation Required

    Suggested Documentation for Selective Neurectomy (SN)

    For selective neurectomy requests, suggest documentation elements that justify progression to surgery after conservative measures and that define the planned procedure and expected outcomes.

    • Document prior use of botulinum toxin (Botox) with dates, doses, intervals, and clinical response
    • Detail neuromuscular retraining efforts (duration, therapy goals, objective measures), synkinesis classification (type II/III), and failure or insufficiency of prior treatments
    • Specify targeted branches for neurectomy/myectomy, anticipated reduction in Botox need, and plans for adjunctive reanimation if applicable
    Step Therapy

    Conservative Management Expected Before Surgery

    Conservative management is expected before considering elective facial surgery. There is no single mandated step-therapy algorithm, but non-surgical options should be trialed and documented prior to authorization for invasive procedures.

    • First-line conservative measures include facial exercises, massage, neuromuscular re‑training, and appropriate medical therapy (see medical sequencing)
    • Document trials of conservative care and objective responses; surgical referral without reasonable conservative attempts should be justified
    Note

    Medical Therapy Sequencing

    Medical therapy sequencing: early systemic corticosteroids are supported for new-onset Bell's palsy; antivirals alone lack clear benefit but may be considered in combination with corticosteroids in selected severe cases.

    • Recommend early prednisolone (within 72 hours) for Bell's palsy as first-line medical therapy
    • Antivirals (acyclovir/valacyclovir) do not add clear benefit alone; combination with corticosteroids may offer incremental benefit in some analyses particularly for severe palsy
    Step Therapy

    Step Therapy: Medications for Bell's Palsy

    Step therapy for medications in Bell's palsy: systemic corticosteroids are the initial therapy; antivirals may be added in severe presentations but are not routinely required.

    • Initial therapy: systemic corticosteroids (prednisone/prednisolone) within recommended window
    • Reserve adding antiviral therapy for severe cases or based on treating clinician judgment and documented rationale
    Step Therapy

    Triage of Synkinesis Therapies

    Triage of therapies for post-paralytic synkinesis should prioritize non-surgical options (chemo-denervation and neuromuscular retraining). Surgical options, including selective neurectomy, are third-line and require documentation of prior therapies and limited response.

    • First-line: botulinum toxin injections (Botox) and structured neuromuscular re‑training
    • Consider SN, myectomy, or reanimation procedures only after adequate trials of first-line therapies with objective documentation of persistent disabling synkinesis
    Step Therapy

    Step Therapy Pathway

    Step therapy pathway for synkinesis: require documented progression through first-line non-surgical interventions before authorizing surgical interventions; selective neurectomy should be reserved for refractory cases.

    • Step 1: Chemo-denervation with botulinum toxin and documented response assessment
    • Step 2: Neuromuscular retraining for an adequate course with objective measures (eFACE, FaCE, House-Brackmann)
    • Step 3: Consider selective neurectomy, myectomy, or reanimation only if Steps 1–2 fail or are contraindicated, with detailed justification

    Codes and Billing

    CPT codes covered if selection criteria are metCPTCovered
    15756Free muscle or myocutaneous flap with microvascular anastomosis
    15758Free fascial flap with microvascular anastomosis
    15840-15845Graft for facial nerve paralysis
    20920-20922Fascia lata graft
    61590Infratemporal pre-auricular approach to middle cranial fossa (parapharyngeal space, infratemporal and midline skull base, nasopharynx), with or without disarticulation of the mandible, including parotidectomy, craniotomy, decompression and/or mobilization of the facial nerve and/or petrous carotid artery
    64716Neuroplasty and/or transposition; cranial nerve (specify)
    64742Transection or avulsion of; facial nerve, differential or complete
    64864-64865Suture of facial nerve
    64866-64868Anastomosis; facial-spinal, facial-hypoglossal or facial-phrenic
    64885-64886Nerve graft (includes obtaining graft), head or neck
    1–10 of 13
    1/2
    CPT/HCPCS codes listed as not covered for indications in CPB (examples)mixedNot Covered
    0232TInjection(s), platelet rich plasma, any site (listed as not covered for indications)
    76536Ultrasound, soft tissues of head and neck (neuromuscular ultrasound) - listed under investigational
    90867-90869Therapeutic repetitive transcranial magnetic stimulation treatment codes (listed under investigational)
    97014Application of modality; electrical stimulation (unattended) - investigational for Bell's palsy
    97810-97814Acupuncture codes - listed as investigational
    99183Physician attendance for hyperbaric oxygen therapy - investigational
    HCPCS codes not covered for indications in CPBHCPCSNot Covered
    A4575Topical hyperbaric oxygen chamber, disposable
    A4595Electrical stimulator supplies, 2 lead, per month (e.g., TENS, NMES)
    A4639Replacement pad for infrared heating pad system, each
    E0221Infrared heating pad system
    E0446Topical oxygen delivery system, not otherwise specified
    E0720TENS device, two lead
    E0730TENS device, four or more leads
    E0745Neuromuscular stimulator, electronic shock unit
    G0277Hyperbaric oxygen under pressure, full body chamber
    J0585Botulinum toxin type A, per unit
    1–10 of 13
    1/2
    ICD-10 codesICD-10
    G51.0Bell's palsy [facial palsy]
    No explicit codes in this document segmentmixed
    No codes listed
    Duration of paralysis for surgical eligibility
    Surgical eligibility duration> 12 months
    Associated functional requirementParalysis must have resulted in impaired mastication, speech, or vision
    Objective testing requirementNo reasonable likelihood of spontaneous return as determined by EMG or electroneuronography
    Applies toFacial reconstructive procedures including anastomosis, fascia slings, muscle transposition, cross‑facial nerve grafting with free muscle transfer

    Definitions and Background

    Bell’s palsy is an acute idiopathic facial nerve (cranial nerve VII) paresis characterized by rapid onset unilateral facial weakness over 24–72 hours. Most patients experience spontaneous recovery within approximately 6 months, although recovery may be delayed in some populations (for example, persons with diabetes). Diagnosis is one of exclusion; electrophysiologic testing such as blink reflex testing and EMG/ENoG can aid in diagnosis and provide prognostic information. Blink reflex testing is specifically listed as a medically necessary diagnostic modality in this policy.

    Bell's palsy
    DefinitionAcute idiopathic facial paresis — rapid onset facial paralysis of cranial nerve VII
    Typical courseUsually self‑limiting with majority recovering spontaneously within 6 months
    PresentationAbrupt unilateral facial weakness over 24–72 hours; may include ear pain, reduced taste, and hyperacusis
    Diagnostic aidsBlink reflex testing and facial EMG have been used; blink reflex sensitivity ~81% and specificity ~94%
    Medically necessary facial surgery criteria
    When surgery is considered necessaryWhen facial paralysis has persisted > 12 months, causes impaired mastication/speech/vision, and EMG/ENoG indicates low likelihood of spontaneous recovery
    Covered procedures examplesAnastomosis with other cranial nerves, fascia slings, muscle transposition, cross‑facial nerve grafting with microvascular muscle transfer
    Timing guidanceIf any early return is noted on EMG, delay further intervention; start consideration if no return at 12 months
    Early treatment
    Initiation windowWithin ~72 hours (Sullivan et al) up to 7 days (Hato et al) of symptom onset
    Primary recommended therapyEarly systemic corticosteroids (prednisolone) increase probability of complete recovery
    Antivirals roleAntivirals alone show no clear benefit; may provide modest additional benefit when combined with steroids in some analyses
    Cross-face nerve graft (CFNG)
    Procedure descriptionCross‑face nerve graft (CFNG) is a staged nerve graft using the contralateral facial nerve to reinnervate paralyzed facial muscles, often followed by free functional muscle transfer
    Typical stagingInitial CFNG followed by gracilis free flap transfer (commonly ~9 months later) to restore spontaneous mimetic function
    IndicationsUsed for long‑standing unilateral irreversible complete palsy when target muscles can still be reinnervated
    Cross-face nerve grafting (CFNG)
    DefinitionCross‑face nerve grafting: use of contralateral healthy facial nerve via grafting to reinnervate paralyzed facial muscles, often part of staged reanimation with free muscle transfer
    GoalRestore spontaneous facial mimetic function and improve symmetry at rest and during expression
    Common sequenceCFNG followed by free functional gracilis transfer for dynamic reanimation
    Masseteric nerve donor transfer
    Donor nerveMotor nerve to the masseter used as donor for single‑stage free functional muscle transfer
    Clinical advantageAllows single‑stage reconstruction with earlier voluntary contraction (observed mean ~2.5 months in small series)
    Use caseOption when earlier reinnervation desired or when CFNG staging is less suitable due to patient factors
    House-Brackmann (HB) scale
    PurposeHouse‑Brackmann (HB) scale is a clinical grading system to assess facial nerve function and quantify severity and recovery
    UsageReferenced throughout trials and reviews as primary outcome measure for facial function
    Scale contextHB grades aid selection for interventions (eg, HB V–VI consistent with severe dysfunction for decompression consideration)
    ENoG and EMG
    TestsElectroneurography (ENoG) and electromyography (EMG) assess degree of nerve degeneration and voluntary motor unit potentials
    Decision roleUsed to determine likelihood of spontaneous recovery and to support surgical decisions (eg, >90% degeneration on ENoG suggests consideration of decompression)
    Timing importanceAbsence of voluntary EMG within ~14 days and high ENoG degeneration are cited in decompression candidate criteria
    Selective neurectomy (SN)
    Procedure intentSelective neurectomy targets specific facial nerve branches to reduce synkinesis and aberrant reinnervation after facial paralysis
    Line of therapyDescribed as adjunctive or third‑line after botulinum toxin and neuromuscular re‑training
    Evidence summaryData limited; systematic review identified 7 studies (250 patients); most studies used Botox before surgery
    Synkinesis
    DefinitionSynkinesis: involuntary facial movements occurring simultaneously with voluntary movements after facial nerve paralysis recovery
    Clinical impactCan detrimentally affect quality of life and function, prompting staged management
    Management contextFirst‑line: botulinum toxin and neuromuscular retraining; surgical options (including SN) considered if refractory